107results about "Cis-trans-isomerases" patented technology

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

The invention discloses a mesophilic carotenoid-producing recombinant yarrowia lipolytica strain as well as a construction method and application thereof, the recombinant strain exogenously expresses mesophilic original fatty acid desaturase (FAD3) and isocitrate dehydrogenase (IDH2) mutants from phaffia rhodozyma, and efficient synthesis under the condition of 30 DEG C is realized; secondly, a metabolic pathway of the recombinant strain is optimized based on a metabolic flow push-pull strategy, and isopentenyl pyrophosphate isomerase (IDI), farnesyl pyrophosphate synthase (ERG20), plant alkene dehydrogenase (CarB) and bifunctional plant alkene synthase (CarRP) are overexpressed, so that the flux of a precursor is increased; finally, gene multi-copy of astaxanthin synthase (crtS) and cytochrome P450 reductase (crtR) from phaffia rhodozyma is carried out, and the carotenoid production capacity of yarrowia lipolytica is further improved. The construction method of the mesophilic yarrowia lipolytica is simple, efficient synthesis of carotenoid can be better achieved at the higher temperature, the fermentation cost is greatly reduced, and the industrial production potential is achieved.

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The invention discloses an application of an NbFKBP13 gene in resisting tomato yellow leaf curl virus. Belongs to the technical field of plant disease control. The overexpression NbFKBP13 transgenic nicotiana benthamiana which can be stably inherited is obtained through a gene engineering technology. Phenotypic observation shows that the NbFKBP13 transgene has no significant influence on the growth and development of nicotiana benthamiana; it is found through artificial inoculation of TYLCV that after overexpression of the NbFKBP13 gene, the resistance of nicotiana benthamiana to TYLCV can be significantly enhanced. The research provides an important gene pool and a new germplasm resource for virus disease resistance breeding.

The invention relates to a recombinant III-type human collagen expression strain with a whole chain length and a triple helix structure as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering bacteria. The recombinant pichia pastoris genetically engineered bacterium expresses recombinant III-type human collagen with a full chain length and a triple helix structure, and a ku70 gene of the recombinant pichia pastoris genetically engineered bacterium is knocked out and knocked in a recombinant 4-proline hydroxylase coding gene and an FKBP22 coding gene. The recombinant pichia pastoris genetically engineered bacterium provided by the invention can be used for obtaining the recombinant full-chain-length triple-helix recombinant III-type human collagen with a higher expression level through high-density fermentation, does not contain heterologous sequences, has higher hydroxyproline content and thermal stability, is close to natural human collagen, has a stable triple-helix structure, is high in thermal stability, and can be used for preparing the recombinant III-type human collagen. The application in the fields of medical health and medical beauty such as medical beauty filling and tissue repair can be met.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention concerns the use of peptidyl-prolyl isomerase cyclophilin 40 (CyP40) for reduction of neurotoxic fibrils and treatment and prevention of neurodegenerative diseases associated with amyloid fibril aggregation. Aspects of the invention include compositions, methods, dosage forms, and kits for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation in a human or animal subject, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using CyP40, or a biologically active fragment thereof.

The present invention relates to means and methods for optimizing expression of a heterologous polypeptide of interest in Gram-positive host cells by co-expression with a foldase that is cognate to the heterologous polypeptide of interest.

The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.

The present disclosure generally relates to compositions and methods for constructing and / or obtaining B. licheniformis cells (e.g., protein-producing hosts) that comprise enhanced protein production capabilities. Accordingly, certain embodiments relate to genetically modified B. licheniformis strains derived from a parent Bacillus licheniformis strain that produce increased amounts of one or more proteins of interest.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

This invention relates to the field of biotechnology, and more particularly to the tobacco NtD27 gene and its applications. Through research on the NtD27 gene, this application has discovered that this gene affects the development of tobacco axillary buds. Knockout mutations of the NtD27 gene can promote the growth of tobacco axillary buds, while overexpression of the NtD27 gene can effectively inhibit the growth of tobacco axillary buds. This provides potential germplasm resource support for molecular breeding of tobacco with fewer axillary buds and has significant practical value in the genetic improvement of important traits in tobacco and in basic botanical research.

The invention relates to a bacillus licheniformis host cell for increasing production of secretory protein. In particular, the present invention relates to a Bacillus licheniformis host having a genetic modification that results in an increased production of heterologous, non-natural, secretory enzymes. Specifically, the present invention relates to a Bacillus licheniformis host cell which expresses a) a first polypeptide having peptidyl-prolyl cis-trans isomerase (EC 5.2. 1.8) activity comprising the amino acid sequence as shown in SEQ ID NO: 1, or at least 81% identical to SEQ ID NO: 1, and b) a second polypeptide having amylase activity comprising the amino acid sequence as shown in SEQ ID NO: 1, or at least 81% identical to SEQ ID NO: 2. Wherein the second polypeptide is heterologous to the Bacillus licheniformis host cell.

The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide modular and tunable protein expression driven by regulated transcriptional activity.

This application relates to a mutant prolyl isomerase and a method for producing glutamate series amino acids using the same.

The present invention provides methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells. The present invention provides methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The invention discloses a targeted exosome loaded with siFKBP10 as well as a preparation method and application of the targeted exosome. The targeted exosome comprises a cell exosome with a membrane protein Lamp2b and a myofibroblast RDYH58 peptide which is combined with the membrane protein, and the cell exosome is modified by the siFKBP10; the cDNA (complementary deoxyribonucleic acid) sequence of the RDYH58 peptide is as shown in SEQ. ID. NO.1; 1, and the positive-sense strand of the siFKBP10 is as shown in SEQ ID NO. 2, and the antisense strand of the siFKBP10 is as shown in SEQ ID NO. 3. The targeting exosome can significantly reduce expression of FKBP10 in cells, inhibits excessive deposition of extracellular matrix, has a good inhibition effect on idiopathic pulmonary fibrosis, and provides a new treatment strategy for treatment of IPF.

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

The present disclosure relates to microbial hosts and methods for the biosynthesis of compositions comprising milk fat triglycerides.

The invention discloses a phoebe bournei constitutive high-expression promoter and application of the phoebe bournei constitutive high-expression promoter in gene expression regulation, and relates to the technical field of plant molecular biology. The nucleotide sequence of the phoebe bournei constitutive high-expression promoter PbCYPpro disclosed by the invention is shown as SEQ ID NO.4. The expression abundance and GUS dyeing effect of a target gene mediated by the promoter PbCYPpro of a PbCYP gene are compared and analyzed, and the drive expression capability of the promoter is found to be remarkably higher than that of a 35S promoter, so that the promoter can replace an exogenous constitutive promoter to improve the expression level of the target gene in a plant body; meanwhile, the transgenic screening efficiency is remarkably optimized, support is provided for efficient expression of Cas protein in a CRISPR gene editing system, and the editing success rate is greatly increased. According to the promoter provided by the invention, the genetic engineering technology blank of the endangered tree species phoebe bournei is filled for the first time, and a core tool is provided for molecular breeding and resource protection.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

The present disclosure relates to engineered depalmitoylases. S-Palmitoylation is a reversible post-translational modification that tunes the localization, stability, and function of an impressive array of proteins including ion channels, G-proteins, and synaptic proteins. Altered protein palmitoylation is linked to various human diseases including cancers, neurodevelopmental and neurodegenerative diseases. Disclosed herein is an engineered chemogenetic depalmitoylase that manipulates the palmitoylation status of target proteins using a chemically inducible dimerization system. In some aspects, the engineered chemogenetic depalmitoylase is programed to allow selective depalmitoylation in specific organelles, of individual protein complexes, or triggered by cell-signaling events. Also disclosed is an engineered depalmitoylase that allows depalmitoylation of proteins in response to Erk phosphorylation. An optogenetic actuator to manipulate protein palmitoylation is also disclosed. The disclosed engineered depalmitoylases represent versatile and powerful methods for manipulating protein palmitoylation in live cells.

The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.

The present invention relates to methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The invention provides an anti-ETEC engineering probiotic as well as a construction method and application thereof, and belongs to the technical field of gene engineering. According to the present invention, lactic acid bacteria are adopted as a presentation vector, a CLA gene coding linoleic acid isomerase in Lactobacillus rhamnosus GG (Lactobacillus rhamnosus) is amplified, and the CLA gene is connected with a Lactobacillus casei ATCC393 (Lactobacillus casei) expression vector pPG 612 so as to construct the engineering bacteria probiotic LC-pPG-CLA; the engineering probiotics have high adhesion and invasion ability to Caco-2 cells, and can competitively inhibit the ETEC K88 strain from adhering to the Caco-2 cells so as to reduce invasion and infection of the ETEC K88 strain to the Caco-2 cells.